The Latest Cardiac and Vascular News
DUBLIN–(BUSINESS WIRE)–CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of severe+ tricuspid regurgitation (TR), announced the first patient treated with the DUO™ System as part of the TANDEM II Early Feasibility Study in the U.S. The DUO™ System is a […]
The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner…
BERLIN and BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) — Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019.It leverages Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–TeraRecon, the leader in medical imaging advanced visualization, clinical AI, and workflow automation, today announced updates to its Intuition platform with new best-in-class cardiac magnetic resonance (MR) medical imaging capabilities. These clinical innovations are now available across all deployment models and on the latest cloud infrastructure. “We are […]
LOS GATOS, Calif., Oct. 23, 2024 /PRNewswire/ — Tioga Cardiovascular, Inc., a Shifamed portfolio company, announced today the first-in-human trans-septal implantations using the 28 Fr. (French) Luna™ transcatheter mitral valve replacement (TMVR) system. The first patients achieved…
Company also named a Finalist in the Fierce Healthcare Innovation Awards OXFORD, England, Oct. 23, 2024 /PRNewswire/ — Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, has been selected a winner of the Digital Health Hub Foundation: Digital…
Next-generation system to be highlighted during a technology innovation session and live case presentation by Professor Jens Erik Nielsen-Kudsk NASHUA, N.H., Oct. 22, 2024 /PRNewswire/ — Conformal Medical, Inc. announced today, the next-generation CLAAS® AcuFORM™ Left Atrial Appendage…
Intravascular Imaging Technology Featuring the World’s Smallest Imaging Catheter Now FDA Cleared for Pre- and Post-Intervention Use. SUDBURY, Mass., Oct. 22, 2024 /PRNewswire/ — Gentuity, LLC, a global leader in advanced intravascular imaging technologies, is pleased to announce that the…
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other prevalent cardiovascular diseases driven by dysregulated aldosterone, today announced full details for its upcoming virtual KOL event being held on Wednesday, October 30, 2024, at 10:00 AM ET. To register for the event, please click here.
NANJING, China, Oct. 22, 2024 /PRNewswire/ — HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for “Allogeneic Human iPSC-derived cardiomyocytes…
